Insights
Search Results
Client Highlights
11.05.26
Wilson Sonsini Advises FluoRok on Patent Matters Related to $30 Million Oversubscribed Series A
On November 5, 2026, FluoRok, a UK company building a manufacturing platform for fluorochemicals that does not require hydrogen fluoride, announced it closed an oversubscribed $30 million Series A financing round. The round was led by Orano Venture Fund/Supernova Invest, alongside investment from Bidra Innovation Ventures and existing investors Oxford Science Enterprises, BGF, GGF, Volta Energy Technologies, and the University of Oxford. Wilson Sonsini Goodrich & Rosati advised FluoRok on patent matters related to the financing.
Client Highlights
10.28.26
Wilson Sonsini Advises Orbus Therapeutics on IP Matters Related to Acquisition by US WorldMeds
On October 27, 2026, US WorldMeds, a specialty pharmaceutical company, and Orbus Therapeutics, a privately held pharmaceutical company developing investigational eflornithine for rare and serious brain tumors, announced a definitive merger agreement under which US WorldMeds has acquired Orbus. Wilson Sonsini Goodrich & Rosati advised Orbus on IP matters in connection with the transaction.
Client Highlights
10.23.26
Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences
On October 22, 2026, Gilead Sciences, a biopharmaceutical company pursuing breakthroughs in medicine, announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company, for $1.275 billion in upfront cash consideration, subject to customary adjustments. The transaction is expected to close later in 2026. Wilson Sonsini Goodrich & Rosati is advising PepStar on patent matters related to the transaction.
Client Highlights
10.14.26
Wilson Sonsini Advises Prolific Machines on Patent and Trademark Matters Related to $50 Million Series B2 Financing
On October 14, 2026, Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions, announced the initial closing of its $50 million Series B2 financing led by Atoms & Bits and Nant Capital. Wilson Sonsini Goodrich & Rosati advised Prolific Machines on patent and trademark matters related to the transaction.
Client Highlights
10.12.26
Firm Advises Oxford Science Enterprises on IP Matters Related to Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47 million in financing to advance and scale its integrated mRNA technology. The financing includes a Series A led by Oxford Science Enterprises (OSE) and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. Wilson Sonsini Goodrich & Rosati advised OSE on IP due diligence related to the transaction.
Client Highlights
10.08.26
Wilson Sonsini Advises Atrium Therapeutics on Patent Matters Related to $50 Million Private Placement
On October 8, 2026, Atrium Therapeutics, a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, announced that it has entered into a securities purchase agreement with a group of leading institutional investors for a private placement financing. The financing is expected to result in aggregate gross proceeds of approximately $50 million, before deducting placement agent fees and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Atrium Therapeutics on patent matters related to the transaction.
Client Highlights
10.08.26
Wilson Sonsini Advises Universal Quantum on IP Matters Related to $100 Million Series A
On October 8, 2026, Universal Quantum, the company building large-scale quantum computing systems for real-world use, announced it has secured over $100 million in Series A funding. The round was co-led by DCVC and Firgun Ventures, with participation from EDBI, Artal (advised by Invus), Integral GlobalTech, Main Sequence, Hostplus, NGS Super, IAG Capital, EdenBase, Eigenstate Holdings, SiteGround Capital, and Dave Baszucki, as well as other existing and new strategic investors. Wilson Sonsini Goodrich & Rosati advised Universal Quantum on patent matters related to the transaction.
9.28.26
Wilson Sonsini Advises ADARx on IP Matters Related to IPO and Concurrent Private Placement
On September 24, 2026, ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced the pricing of its upsized initial public offering (IPO) of 26,250,000 shares of common stock at $17.00 per share. All of the shares of common stock are being offered by ADARx. The shares began trading on the Nasdaq Global Select Market on September 25, 2026, under the ticker symbol “ADRX.”
Client Highlights
9.10.26
Wilson Sonsini Advises Kura Oncology on Patent Matters Related to Launch of Caspian Therapeutics
On September 9, 2026, Kura Oncology (Kura), a biopharmaceutical company focused on precision medicines for the treatment of cancer, announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian was established around KO-7246, a next-generation, highly selective menin inhibitor purpose-designed for chronic metabolic diseases, together with related intellectual property and know-how contributed by Kura. Kura will retain approximately half ownership of Caspian and board representation. Caspian will operate with dedicated leadership and external capital with access to Kura’s research, development, and corporate capabilities under an intercompany services arrangement. Wilson Sonsini Goodrich & Rosati advised Kura on patent matters related to the transaction.
Client Highlights
8.13.26
Firm Advises Khartis Therapeutics on Patent Matters Related to $50 Million Series B
On August 13, 2026, Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing total capital raised to $95 million. Wilson Sonsini Goodrich & Rosati advised Khartis on patent matters related to the transaction and has served as patent counsel for the company since its inception in 2024.
Client Highlights
8.11.26
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
Client Highlights
8.11.26
Firm Advises Expedition Therapeutics on Patent Matters Related to $115 Million Series B
On August 5, 2026, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B financing led by General Atlantic, a leading global investor, with participation from RA Capital and Vivo Capital and existing investors Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma (a platform controlled by KKR), Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati is patent counsel to Expedition and advises the company on all patent matters, including those related to this transaction.